- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03031275
Long-term Follow Up of Adult Patients Treated With Extracorporeal Membrane Oxygenation for Respiratory Failure
Follow-up after treatment with Extracorporeal Membrane Oxygenation (ECMO) at the ECMO Center Karolinska.
Patients: adult survivors treated with ECMO for severe refractory respiratory failure at least 5 years earlier.
Investigations: brain and pulmonary radiographic morphology, cognitive testing, pulmonary function testing, exercise tolerance, quality of life and mood disorder screening.
Study Overview
Status
Conditions
Detailed Description
All adult patients treated at the ECMO Center Karolinska between 1995 and July 2009 were screened for eligibility in January 2014. Patients living abroad (including non-Swedish citizens), patients treated for non-respiratory conditions, diseased patients and patients with a known pre-ECMO mental handicap were excluded.
Eligible patients were contacted, and patients who agreed to participate gave their written informed consent. All studied patients underwent the same study protocol during a day at the hospital, including a clinical interview, MRI scan of the brain, HRCT scan of the thorax, pulmonary function testing, neuropsychological examination, walking test, self assessment questionnaires for quality of life, anxiety, depression and post-traumatic stress.
Patient charts were reviewed for relevant clinical information, including age, gender, ECMO mode (venovenous or venoarterial), time in hospital, on ECMO, non-ECMO ICU and on mechanical ventilation; preexisting diseases, blood gas values and ventilator settings before initiation of ECMO treatment. Hand written clinical data from the patients´ charts from every hour with ECMO treatment was reviewed for ventilator settings, lung volumes, mean arterial pressure, hemoglobin, lactate and oxygenation parameters during an observation period, which was defined as the first 10 days on ECMO (or the entire treatment period if shorter than 10 days). This information was added to a digital database for the purpose of this study.
At the time of ECMO treatment, arterial hemoglobin oxygen saturation was measured by peripheral pulse oximetry from the right ear, finger or nose. Venous preoxygenator lactate and venous saturation values were used as indicators of sufficient (lactate < 2 mmol l-1 , SvO2 ≥ 70%) or insufficient tissue perfusion.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden, 17176
- ECMO Center Karolinska
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients treated with ECMO at the ECMO Center Karolinska 1995 - July 2009
Exclusion Criteria:
- Diseased patients
- Patients living abroad (including non-Swedish citizens)
- Patients treated for non-respiratory conditions
- Patients with a known pre-ECMO mental handicap
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with abnormal cognitive functioning assessed by the Wechsler Adult Intelligence Scale and memory tests
Time Frame: 5-17 years after treatment
|
Wechsler Adult Intelligence Scale, 4th ed, Rey Auditory Verbal Learning Test (learning trials 1 to 5 and delayed recall), immediate recall from the Rey Complex Figure and Logical Memory I and II from Wechsler Memory Scale, 3rd ed.
|
5-17 years after treatment
|
Number of participants with abnormal brain imaging assessed by magnetic resonance imaging
Time Frame: 5-17 years after treatment
|
Sagittal and axial T1- and T2-weighted images, and coronal T2-weighted and T2-weighted fluid attenuated inversion recovery (FLAIR) images.
Slice thickness 4 mm.
Presence of hypoxic or anoxic damage, infarctions, hemorrhages, and contusion damage were described.
|
5-17 years after treatment
|
Number of Participants With Abnormal Pulmonary function
Time Frame: 5-17 years after treatment
|
Static and dynamic spirometry.
Measured results as % of the expected normal values were presented.
|
5-17 years after treatment
|
Number of Participants With Abnormal Lungs radiographic findings assessed by high-resolution CT scan
Time Frame: 5-17 years after treatment
|
Non-contrast spiral scan.
A series for grading of pulmonary changes was reconstructed, using a high spatial resolution reconstruction algorithm with 1 mm-width, overlapping slices.
Four patterns were mapped: reticular, ground-glass opacification, consolidation and decreased attenuation.
|
5-17 years after treatment
|
Number of participants with signs of post-traumatic stress assessed by the Trauma Screening Questionnaire
Time Frame: 5-17 years after treatment
|
5-17 years after treatment
|
|
Number of participants with signs of a reduced health related quality-of-life, assessed by the Short Form-36
Time Frame: 5-17 years after treatment
|
5-17 years after treatment
|
|
Number of participants with signs of a reduced Health related quality-of-life, assessed by the S:t George´s Respiratory Questionnaire
Time Frame: 5-17 years after treatment
|
5-17 years after treatment
|
|
Number of participants with signs of a reduced exercise tolerance
Time Frame: 5-17 years after treatment
|
6-minute walking test
|
5-17 years after treatment
|
Number of participants with signs of anxiety and depression assessed by the Hospital and Anxiety Depression Scale
Time Frame: 5-17 years after treatment
|
5-17 years after treatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013/2258-31/1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia
-
King Edward Memorial HospitalCompletedNosocomial Pneumonia | Healthcare-Associated Pneumonia | Aspiration Pneumonia | Ventilator-Associated PneumoniaIndia
-
Melinta Therapeutics, Inc.WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
Venatorx Pharmaceuticals, Inc.Biomedical Advanced Research and Development AuthorityNot yet recruitingHospital-acquired Pneumonia | Ventilator-associated Pneumonia
-
Hannover Medical SchoolCharite University, Berlin, Germany; University of LeipzigUnknownCOVID-19 | Bacterial Pneumonia | Viral Pneumonia | Pneumonia Due to Streptococcus Pneumoniae | Pneumonia Due to H. Influenzae | Pneumonia, Organism Unspecified | Pneumonia in Diseases Classified Elsewhere | Pneumonia Due to Other Specified Infectious OrganismsGermany
-
Nantes University HospitalSociété Française d'Anesthésie et de RéanimationCompletedPneumonia | Sepsis | Ventilator-Associated Pneumonia | Hospital Acquired PneumoniaFrance
-
University Medical Centre LjubljanaUniversity of Ljubljana, Faculty of MedicineUnknownCommunity Acquired Pneumonia | Ventilator Associated Pneumonia | Hospital Acquired PneumoniaSlovenia
-
PfizerCompletedVentilator-associated Pneumonia (VAP) | Nosocomial Pneumonia (NP)Bulgaria, France, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Turkey, United Kingdom, Vietnam, Philippines, China, Ukraine, Argentina, Brazil, Hungary, Romania, India, Japan, Taiwan, Latvia, Czechia, Slov... and more
-
Arpida AGTerminatedHospital-Acquired Pneumonia | Ventilator-Associated Pneumonia | Health-Care-Associated Pneumonia
-
ShionogiCompletedHospital Acquired Pneumonia (HAP) | Healthcare-associated Pneumonia (HCAP) | Ventilator Associated Pneumonia (VAP)Israel, Spain, United States, Belgium, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Japan, Latvia, Philippines, Puerto Rico, Russian Federation, Serbia, Taiwan, Ukraine
-
Methodist Health SystemCompletedHospital-acquired Pneumonia | Ventilator-associated PneumoniaUnited States
Clinical Trials on High-resolution computed tomography
-
Assiut UniversityUnknownIdiopathic Pulmonary Fibrosis
-
Beijing Friendship HospitalBeijing Tongren Hospital; Beijing Obstetrics and Gynecology HospitalRecruitingVertigo | Hearing Loss | TinnitusChina
-
FLUIDDA nvCompletedChanges in Upper Airway GeometryBelgium
-
University of California, San FranciscoCompletedOsteoporosisUnited States
-
Assiut UniversityUnknown
-
FLUIDDA nvCompletedBronchiolitis Obliterans | Lung Transplant RejectionBelgium
-
FLUIDDA nvTerminatedBronchiolitis Obliterans | Lung Transplant RejectionBelgium
-
FLUIDDA nvCompletedBronchiolitis Obliterans | Lung Transplant RejectionUnited States
-
University of California, San FranciscoCompletedType 2 DiabetesUnited States